View ValuationSitara Peroxide 将来の成長Future 基準チェック /06現在、 Sitara Peroxideの成長と収益を予測するのに十分なアナリストの調査がありません。主要情報n/a収益成長率n/aEPS成長率Chemicals 収益成長25.9%収益成長率n/a将来の株主資本利益率n/aアナリストカバレッジNone最終更新日n/a今後の成長に関する最新情報Price Target Changed • Oct 07Price target decreased to PK₨31.00Down from PK₨36.50, the current price target is provided by 1 analyst. New target price is 43% above last closing price of PK₨21.62. Stock is down 6.3% over the past year.すべての更新を表示Recent updatesValuation Update With 7 Day Price Move • Apr 27Investor sentiment improves as stock rises 15%After last week's 15% share price gain to PK₨59.90, the stock trades at a trailing P/E ratio of 22.1x. Average trailing P/E is 11x in the Chemicals industry in Pakistan. Total returns to shareholders of 328% over the past three years.お知らせ • Apr 22Sitara Peroxide Limited to Report Q3, 2026 Results on Apr 29, 2026Sitara Peroxide Limited announced that they will report Q3, 2026 results on Apr 29, 2026お知らせ • Feb 24Sitara Peroxide Limited to Report First Half, 2026 Results on Feb 28, 2026Sitara Peroxide Limited announced that they will report first half, 2026 results on Feb 28, 2026New Risk • Feb 17New major risk - Market cap sizeThe company's market capitalization is less than US$10m. Market cap: PK₨2.79b (US$9.97m) This is considered a major risk. Companies with a small market capitalization are most likely businesses that have not yet released a product to market or are simply a very small company without a wide reach. Either way, risk is elevated with these companies because there is a chance the product may not come to fruition or the company's addressable market or demand may not be as large as expected. In addition, if the company's size is the main factor, it is less likely to have many investors and analysts following it and scrutinizing its performance and outlook. Currently, the following risks have been identified for the company: Major Risks Share price has been highly volatile over the past 3 months (14% average weekly change). Earnings have declined by 25% per year over the past 5 years. Revenue is less than US$1m. Market cap is less than US$10m (PK₨2.79b market cap, or US$9.97m).Board Change • Feb 13Less than half of directors are independentFollowing the recent departure of a director, there are only 2 independent directors on the board. The company's board is composed of: 2 independent directors. 5 non-independent directors. Independent Director Saim Bin Saeed was the last independent director to join the board, commencing their role in 2022. The company's minority of independent directors is a risk according to the Simply Wall St Risk Model.お知らせ • Jan 20Sitara Peroxide Limited to Report Q1, 2026 Results on Jan 27, 2026Sitara Peroxide Limited announced that they will report Q1, 2026 results at 12:30 PM, Pakistan Standard Time on Jan 27, 2026お知らせ • Jan 08Sitara Peroxide Limited Announces Directorate AppointmentsSitara Peroxide Limited, at the EGM held on January 7, 2026 approved appointment of Mr. Muhammad Bin Imran and Mr. Muhammad Iqbal as directors.お知らせ • Oct 31Sitara Peroxide Limited to Report Fiscal Year 2025 Results on Nov 07, 2025Sitara Peroxide Limited announced that they will report fiscal year 2025 results at 9:30 AM, Pakistan Standard Time on Nov 07, 2025New Risk • Sep 12New major risk - Share price stabilityThe company's share price has been highly volatile over the past 3 months. It is more volatile than 90% of Pakistani stocks, typically moving 9.3% a week. This is considered a major risk. Share price volatility increases the risk of potential losses in the short-term as the stock tends to have larger drops in price more frequently than other stocks. It may also indicate the stock is highly sensitive to market conditions or economic conditions rather than being sensitive to its own business performance, which may also be inconsistent. Currently, the following risks have been identified for the company: Major Risks Share price has been highly volatile over the past 3 months (9.3% average weekly change). Revenue has declined by 98% over the past year. Revenue is less than US$1m (PK₨15m revenue, or US$53k). Market cap is less than US$10m (PK₨1.45b market cap, or US$5.14m).New Risk • Aug 09New minor risk - Share price stabilityThe company's share price has been volatile over the past 3 months. It is more volatile than 75% of Pakistani stocks, typically moving 8.5% a week. This is considered a minor risk. Share price volatility indicates the stock is highly sensitive to market conditions or economic conditions rather than being sensitive to its own business performance, which may also be inconsistent. It also increases the risk of potential losses in the short term as the stock tends to have larger drops in price more frequently than other stocks. Currently, the following risks have been identified for the company: Major Risks Revenue has declined by 98% over the past year. Revenue is less than US$1m (PK₨15m revenue, or US$53k). Market cap is less than US$10m (PK₨970.9m market cap, or US$3.44m). Minor Risk Share price has been volatile over the past 3 months (8.5% average weekly change).お知らせ • Aug 01Sitara Peroxide Limited, Annual General Meeting, Aug 22, 2025Sitara Peroxide Limited, Annual General Meeting, Aug 22, 2025.New Risk • Jul 01New major risk - Financial data availabilityThe company has not reported any financial data. This is considered a major risk. With no or incomplete audited reported financial data, it is virtually impossible to assess the company's investment potential. Currently, the following risks have been identified for the company: Major Risks No financial data reported. Market cap is less than US$10m (PK₨820.4m market cap, or US$2.89m).New Risk • Mar 30New major risk - Financial data availabilityThe company has not reported any financial data. This is considered a major risk. With no or incomplete audited reported financial data, it is virtually impossible to assess the company's investment potential. Currently, the following risks have been identified for the company: Major Risks No financial data reported. Market cap is less than US$10m (PK₨664.0m market cap, or US$2.37m).Reported Earnings • Dec 19First quarter 2024 earnings released: PK₨1.43 loss per share (vs PK₨1.98 loss in 1Q 2023)First quarter 2024 results: PK₨1.43 loss per share (improved from PK₨1.98 loss in 1Q 2023). Revenue: PK₨15.9m (down 95% from 1Q 2023). Net loss: PK₨78.8m (loss narrowed 28% from 1Q 2023).Reported Earnings • Sep 27Full year 2023 earnings released: PK₨14.39 loss per share (vs PK₨6.19 loss in FY 2022)Full year 2023 results: PK₨14.39 loss per share (further deteriorated from PK₨6.19 loss in FY 2022). Revenue: PK₨824.0m (down 53% from FY 2022). Net loss: PK₨792.8m (loss widened 132% from FY 2022).お知らせ • Sep 27Sitara Peroxide Limited, Annual General Meeting, Oct 10, 2024Sitara Peroxide Limited, Annual General Meeting, Oct 10, 2024.New Risk • Aug 26New minor risk - Share price stabilityThe company's share price has been volatile over the past 3 months. It is more volatile than 75% of Pakistani stocks, typically moving 7.0% a week. This is considered a minor risk. Share price volatility indicates the stock is highly sensitive to market conditions or economic conditions rather than being sensitive to its own business performance, which may also be inconsistent. It also increases the risk of potential losses in the short term as the stock tends to have larger drops in price more frequently than other stocks. Currently, the following risks have been identified for the company: Major Risks Latest financial reports are more than 1 year old (reported March 2023 fiscal period end). Revenue has declined by 64% over the past year. Market cap is less than US$10m (PK₨783.0m market cap, or US$2.81m). Minor Risks Share price has been volatile over the past 3 months (7.0% average weekly change). Revenue is less than US$5m (PK₨720m revenue, or US$2.6m).お知らせ • Jul 23Sitara Peroxide Limited, Annual General Meeting, Jul 26, 2024Sitara Peroxide Limited, Annual General Meeting, Jul 26, 2024, at 15:00 Pakistan Standard Time. Agenda: To consider the pending approval of the audited financial statments along with subsequent developments and way-forward; to consider the pending approval of the balancing, modernization and replacement of the company, the financial arrangementas and way-forward; and to consider other matters.New Risk • May 05New major risk - Financial data availabilityThe company's latest financial reports are more than a year old. Last reported fiscal period ended March 2023. This is considered a major risk. If the company has not reported its earnings on time, it may have been delayed due to audit problems or it may be finding it difficult to reconcile its accounts. In the worst case scenario, it may be facing other major going concern issues jeopardizing its viability as a listed company. Currently, the following risks have been identified for the company: Major Risks Latest financial reports are more than 1 year old (reported March 2023 fiscal period end). Revenue has declined by 64% over the past year. Market cap is less than US$10m (PK₨771.4m market cap, or US$2.77m). Minor Risk Revenue is less than US$5m (PK₨720m revenue, or US$2.6m).New Risk • Nov 21New minor risk - Financial data availabilityThe company's latest financial reports are more than 6 months old. Last reported fiscal period ended March 2023. This is considered a minor risk. If the company has not reported its earnings on time, it may have been delayed due to audit problems or it may be finding it difficult to reconcile its accounts. Currently, the following risks have been identified for the company: Major Risks Less than 1 year of cash runway based on free cash flow trend (-PK₨139m free cash flow). Share price has been highly volatile over the past 3 months (8.8% average weekly change). Earnings have declined by 56% per year over the past 5 years. Market cap is less than US$10m (PK₨933.9m market cap, or US$3.27m). Minor Risks Latest financial reports are more than 6 months old (reported March 2023 fiscal period end). Revenue is less than US$5m (PK₨720m revenue, or US$2.5m).New Risk • Oct 18New minor risk - Share price stabilityThe company's share price has been volatile over the past 3 months. It is more volatile than 75% of Pakistani stocks, typically moving 6.2% a week. This is considered a minor risk. Share price volatility indicates the stock is highly sensitive to market conditions or economic conditions rather than being sensitive to its own business performance, which may also be inconsistent. It also increases the risk of potential losses in the short term as the stock tends to have larger drops in price more frequently than other stocks. Currently, the following risks have been identified for the company: Major Risks Less than 1 year of cash runway based on free cash flow trend (-PK₨139m free cash flow). Earnings have declined by 56% per year over the past 5 years. Market cap is less than US$10m (PK₨750.5m market cap, or US$2.71m). Minor Risks Share price has been volatile over the past 3 months (6.2% average weekly change). Revenue is less than US$5m (PK₨720m revenue, or US$2.6m).Reported Earnings • Apr 08Second quarter 2023 earnings released: PK₨2.01 loss per share (vs PK₨0.13 profit in 2Q 2022)Second quarter 2023 results: PK₨2.01 loss per share (down from PK₨0.13 profit in 2Q 2022). Revenue: PK₨70.6m (down 89% from 2Q 2022). Net loss: PK₨111.0m (down PK₨118.2m from profit in 2Q 2022). Over the last 3 years on average, the company's share price growth rate has exceeded its earnings growth rate by 101 percentage points per year, which is a significant difference in performance.Board Change • Nov 16Less than half of directors are independentThere is 1 new director who has joined the board in the last 3 years. The new board member was an independent director. The company's board is composed of: 1 new director. 6 experienced directors. No highly experienced directors. 2 independent directors (5 non-independent directors). Independent Director Saim Bin Saeed was the last independent director to join the board, commencing their role in 2022. The following issues are considered to be risks according to the Simply Wall St Risk Model: Minority of independent directors. Insufficient board refreshment.お知らせ • Nov 12Sitara Peroxide Limited Appoints Yasir Ahmed Awan as ChairmanSitara Peroxide Limited announced that Mr. Yasir Ahmed Awan has been appointed as Chairman of the Board of Directors of the Company and Mr. Imran Ghafoor as Chief Executive Officer for a term of three years.お知らせ • Aug 19Sitara Peroxide Limited Appoints Saim Bin Saeed as DirectorSitara Peroxide Limited informed Pakistan Stock Exchange that Mr. Saim Bin Saeed has been appointed as Director of the company with effect from August 17, 2022 in place of Mr. Mahmood Ahmad.お知らせ • Jun 03Sitara Peroxide Limited Announces Resignation of Mahmood Ahmad as DirectorSitara Peroxide Limited informed Pakistan Stock Exchange that Mr. Mahmood Ahmad has resigned from the post of Director of the company with effect from May 30, 2022.Board Change • Apr 27Less than half of directors are independentNo new directors have joined the board in the last 3 years. The company's board is composed of: No new directors. 7 experienced directors. No highly experienced directors. 2 independent directors (5 non-independent directors). Non-Executive Director Ejaz Hussain was the last director to join the board, commencing their role in 2016. The following issues are considered to be risks according to the Simply Wall St Risk Model: Minority of independent directors. Insufficient board refreshment.Reported Earnings • Nov 01First quarter 2022 earnings released: PK₨1.80 loss per share (vs PK₨0.92 profit in 1Q 2021)The company reported a poor first quarter result with weaker earnings, revenues and control over costs. First quarter 2022 results: Revenue: PK₨450.5m (down 21% from 1Q 2021). Net loss: PK₨99.0m (down 294% from profit in 1Q 2021). Over the last 3 years on average, earnings per share has fallen by 49% per year but the company’s share price has only fallen by 15% per year, which means it has not declined as severely as earnings.Price Target Changed • Oct 07Price target decreased to PK₨31.00Down from PK₨36.50, the current price target is provided by 1 analyst. New target price is 43% above last closing price of PK₨21.62. Stock is down 6.3% over the past year.Reported Earnings • Sep 28Full year 2021 earnings released: EPS PK₨0.63 (vs PK₨1.35 in FY 2020)The company reported a soft full year result with weaker earnings and profit margins, although revenues improved. Full year 2021 results: Revenue: PK₨1.87b (up 6.9% from FY 2020). Net income: PK₨34.7m (down 53% from FY 2020). Profit margin: 1.9% (down from 4.3% in FY 2020). Over the last 3 years on average, earnings per share has fallen by 5% per year but the company’s share price has fallen by 14% per year, which means it is performing significantly worse than earnings.Valuation Update With 7 Day Price Move • Sep 27Investor sentiment deteriorated over the past weekAfter last week's 16% share price decline to PK₨21.00, the stock trades at a trailing P/E ratio of 5.7x. Average forward P/E is 17x in the Chemicals industry in Pakistan. Total loss to shareholders of 32% over the past three years.Executive Departure • Jul 13Chief Financial Officer Kamran Zahoor has left the companyDuring their tenure, the company went from making losses to turning a profit. On the 30th of June, Kamran Zahoor left the company after 3.3 in the role. We don't have any record of a personal shareholding under Kamran's name. Kamran is the only executive to leave the company over the last 12 months.Reported Earnings • May 02Third quarter 2021 earnings released: EPS PK₨0.44 (vs PK₨0.15 in 3Q 2020)The company reported a decent third quarter result with improved earnings and profit margins, although revenues were weaker. Third quarter 2021 results: Revenue: PK₨447.8m (down 3.8% from 3Q 2020). Net income: PK₨24.3m (up 200% from 3Q 2020). Profit margin: 5.4% (up from 1.7% in 3Q 2020). The increase in margin was driven by lower expenses. Over the last 3 years on average, earnings per share has increased by 30% per year but the company’s share price has only increased by 8% per year, which means it is significantly lagging earnings growth.Reported Earnings • Feb 28Second quarter 2021 earnings released: EPS PK₨0.83 (vs PK₨0.40 loss in 2Q 2020)The company reported a decent second quarter result with improved earnings and profit margins, although revenues were weaker. Second quarter 2021 results: Revenue: PK₨497.2m (down 7.4% from 2Q 2020). Net income: PK₨45.6m (up PK₨67.8m from 2Q 2020). Profit margin: 9.2% (up from net loss in 2Q 2020). The move to profitability was driven by lower expenses. Over the last 3 years on average, earnings per share has increased by 43% per year but the company’s share price has only increased by 19% per year, which means it is significantly lagging earnings growth.Valuation Update With 7 Day Price Move • Feb 01Investor sentiment improved over the past weekAfter last week's 19% share price gain to PK₨32.76, the stock is trading at a trailing P/E ratio of 15.3x, up from the previous P/E ratio of 12.8x. This compares to an average P/E of 14x in the Chemicals industry in Pakistan. Total returns to shareholders over the past three years are 66%.Is New 90 Day High Low • Jan 27New 90-day high: PK₨30.16The company is up 36% from its price of PK₨22.13 on 29 October 2020. The Pakistani market is up 10.0% over the last 90 days, indicating the company outperformed over that time. It also outperformed the Chemicals industry, which is up 5.0% over the same period.Valuation Update With 7 Day Price Move • Jan 06Investor sentiment improved over the past weekAfter last week's 17% share price gain to PK₨26.91, the stock is trading at a trailing P/E ratio of 12.5x, up from the previous P/E ratio of 10.7x. This compares to an average P/E of 13x in the Chemicals industry in Pakistan. Total returns to shareholders over the past three years are 59%.Is New 90 Day High Low • Jan 05New 90-day high: PK₨25.04The company is up 8.0% from its price of PK₨23.22 on 07 October 2020. The Pakistani market is up 11% over the last 90 days, indicating the company underperformed over that time. However, it outperformed the Chemicals industry, which is up 7.0% over the same period.Reported Earnings • Oct 23First quarter earnings releasedOver the last 12 months the company has reported total profits of PK₨119.9m, up 67% from the prior year. Total revenue was PK₨1.92b over the last 12 months, up 2.3% from the prior year.Reported Earnings • Oct 06Full year earnings released - EPS PK₨1.35Over the last 12 months the company has reported total profits of PK₨74.2m, down 64% from the prior year. Total revenue was PK₨1.75b over the last 12 months, down 14% from the prior year. Profit margins were 4.3%, which is lower than the 10% margin from last year. The decrease in margin was driven by lower revenue.Reported Earnings • Sep 30Full year earnings released - EPS PK₨1.35Over the last 12 months the company has reported total profits of PK₨74.2m, down 64% from the prior year. Total revenue was PK₨1.75b over the last 12 months, down 14% from the prior year. Profit margins were 4.3%, which is lower than the 10% margin from last year. The decrease in margin was driven by lower revenue. このセクションでは通常、投資家が会社の利益創出能力を理解する一助となるよう、プロのアナリストのコンセンサス予想に基づく収益と利益の成長予測を提示する。しかし、Sitara Peroxide は十分な過去のデータを提供しておらず、アナリストの予測もないため、過去のデータを外挿したり、アナリストの予測を使用しても、その将来の収益を確実に算出することはできません。 シンプリー・ウォール・ストリートがカバーする企業の97%は過去の財務データを持っているため、これはかなり稀な状況です。 業績と収益の成長予測KASE:SPL - アナリストの将来予測と過去の財務データ ( )PKR Millions日付収益収益フリー・キャッシュフロー営業活動によるキャッシュ平均アナリスト数3/31/2026N/A177-51-51N/A12/31/20250149-74-74N/A9/30/2025N/A-20100N/A6/30/2025N/A-2232020N/A3/31/2025N/A-209-4-4N/A12/31/2024N/A-21777N/A9/30/2024-1-1612929N/A6/30/202415-169-5-5N/A3/31/2024317-566-64-64N/A12/31/2023453-589-37-36N/A9/30/2023525-702-89-81N/A6/30/2023824-733-203-195N/A3/31/2023720-502-139-127N/A12/31/20221,084-469-138-130N/A9/30/20221,607-351-119-116N/A6/30/20221,743-34147N/A3/31/20222,014-228-76143N/A12/31/20211,978-154-42181N/A9/30/20211,746-115-100123N/A6/30/20211,8653554277N/A3/31/20211,745204203219N/A12/31/20201,745188160176N/A9/30/20201,921120262275N/A6/30/20201,74574143156N/A3/31/20201,906-12356347N/A12/31/20191,9176N/A153N/A9/30/20191,87773N/A239N/A6/30/20192,036207N/A221N/A3/31/20192,042298N/A54N/A12/31/20181,889246N/A162N/A9/30/20181,627157N/A29N/A6/30/20181,322-65N/A90N/A3/31/20181,108-148N/A-11N/A12/31/20171,078-129N/A104N/A9/30/20171,119-80N/A126N/A6/30/20171,060-87N/A53N/A3/31/20171,053-101N/A158N/A12/31/20161,098-72N/A237N/A9/30/20161,168-83N/A283N/A6/30/20161,31017N/A320N/A3/31/20161,37711N/A239N/A12/31/20151,371-38N/A168N/A9/30/20151,334-18N/A173N/A6/30/20151,325-51N/A127N/Aもっと見るアナリストによる今後の成長予測収入対貯蓄率: SPLの予測収益成長が 貯蓄率 ( 12.9% ) を上回っているかどうかを判断するにはデータが不十分です。収益対市場: SPLの収益がPK市場よりも速く成長すると予測されるかどうかを判断するにはデータが不十分です高成長収益: SPLの収益が今後 3 年間で 大幅に 増加すると予想されるかどうかを判断するにはデータが不十分です。収益対市場: SPLの収益がPK市場よりも速く成長すると予測されるかどうかを判断するにはデータが不十分です。高い収益成長: SPLの収益が年間20%よりも速く成長すると予測されるかどうかを判断するにはデータが不十分です。一株当たり利益成長率予想将来の株主資本利益率将来のROE: SPLの 自己資本利益率 が 3 年後に高くなると予測されるかどうかを判断するにはデータが不十分です成長企業の発掘7D1Y7D1Y7D1YMaterials 業界の高成長企業。View Past Performance企業分析と財務データの現状データ最終更新日（UTC時間）企業分析2026/05/17 15:41終値2026/05/15 00:00収益2026/03/31年間収益2025/06/30データソース企業分析に使用したデータはS&P Global Market Intelligence LLC のものです。本レポートを作成するための分析モデルでは、以下のデータを使用しています。データは正規化されているため、ソースが利用可能になるまでに時間がかかる場合があります。パッケージデータタイムフレーム米国ソース例会社財務10年損益計算書キャッシュ・フロー計算書貸借対照表SECフォーム10-KSECフォーム10-Qアナリストのコンセンサス予想+プラス3年予想財務アナリストの目標株価アナリストリサーチレポートBlue Matrix市場価格30年株価配当、分割、措置ICEマーケットデータSECフォームS-1所有権10年トップ株主インサイダー取引SECフォーム4SECフォーム13Dマネジメント10年リーダーシップ・チーム取締役会SECフォーム10-KSECフォームDEF 14A主な進展10年会社からのお知らせSECフォーム8-K* 米国証券を対象とした例であり、非米国証券については、同等の規制書式および情報源を使用。特に断りのない限り、すべての財務データは1年ごとの期間に基づいていますが、四半期ごとに更新されます。これは、TTM（Trailing Twelve Month）またはLTM（Last Twelve Month）データとして知られています。詳細はこちら。分析モデルとスノーフレーク本レポートを生成するために使用した分析モデルの詳細は当社のGithubページでご覧いただけます。また、レポートの使用方法に関するガイドやYoutubeのチュートリアルも掲載しています。シンプリー・ウォールストリート分析モデルを設計・構築した世界トップクラスのチームについてご紹介します。業界およびセクターの指標私たちの業界とセクションの指標は、Simply Wall Stによって6時間ごとに計算されます。アナリスト筋Sitara Peroxide Limited 0 これらのアナリストのうち、弊社レポートのインプットとして使用した売上高または利益の予想を提出したのは、 。アナリストの投稿は一日中更新されます。2 アナリスト機関Noor ShaikhBMA Capital Management Ltd.null nullInsight Securities (Private) Limited
Price Target Changed • Oct 07Price target decreased to PK₨31.00Down from PK₨36.50, the current price target is provided by 1 analyst. New target price is 43% above last closing price of PK₨21.62. Stock is down 6.3% over the past year.
Valuation Update With 7 Day Price Move • Apr 27Investor sentiment improves as stock rises 15%After last week's 15% share price gain to PK₨59.90, the stock trades at a trailing P/E ratio of 22.1x. Average trailing P/E is 11x in the Chemicals industry in Pakistan. Total returns to shareholders of 328% over the past three years.
お知らせ • Apr 22Sitara Peroxide Limited to Report Q3, 2026 Results on Apr 29, 2026Sitara Peroxide Limited announced that they will report Q3, 2026 results on Apr 29, 2026
お知らせ • Feb 24Sitara Peroxide Limited to Report First Half, 2026 Results on Feb 28, 2026Sitara Peroxide Limited announced that they will report first half, 2026 results on Feb 28, 2026
New Risk • Feb 17New major risk - Market cap sizeThe company's market capitalization is less than US$10m. Market cap: PK₨2.79b (US$9.97m) This is considered a major risk. Companies with a small market capitalization are most likely businesses that have not yet released a product to market or are simply a very small company without a wide reach. Either way, risk is elevated with these companies because there is a chance the product may not come to fruition or the company's addressable market or demand may not be as large as expected. In addition, if the company's size is the main factor, it is less likely to have many investors and analysts following it and scrutinizing its performance and outlook. Currently, the following risks have been identified for the company: Major Risks Share price has been highly volatile over the past 3 months (14% average weekly change). Earnings have declined by 25% per year over the past 5 years. Revenue is less than US$1m. Market cap is less than US$10m (PK₨2.79b market cap, or US$9.97m).
Board Change • Feb 13Less than half of directors are independentFollowing the recent departure of a director, there are only 2 independent directors on the board. The company's board is composed of: 2 independent directors. 5 non-independent directors. Independent Director Saim Bin Saeed was the last independent director to join the board, commencing their role in 2022. The company's minority of independent directors is a risk according to the Simply Wall St Risk Model.
お知らせ • Jan 20Sitara Peroxide Limited to Report Q1, 2026 Results on Jan 27, 2026Sitara Peroxide Limited announced that they will report Q1, 2026 results at 12:30 PM, Pakistan Standard Time on Jan 27, 2026
お知らせ • Jan 08Sitara Peroxide Limited Announces Directorate AppointmentsSitara Peroxide Limited, at the EGM held on January 7, 2026 approved appointment of Mr. Muhammad Bin Imran and Mr. Muhammad Iqbal as directors.
お知らせ • Oct 31Sitara Peroxide Limited to Report Fiscal Year 2025 Results on Nov 07, 2025Sitara Peroxide Limited announced that they will report fiscal year 2025 results at 9:30 AM, Pakistan Standard Time on Nov 07, 2025
New Risk • Sep 12New major risk - Share price stabilityThe company's share price has been highly volatile over the past 3 months. It is more volatile than 90% of Pakistani stocks, typically moving 9.3% a week. This is considered a major risk. Share price volatility increases the risk of potential losses in the short-term as the stock tends to have larger drops in price more frequently than other stocks. It may also indicate the stock is highly sensitive to market conditions or economic conditions rather than being sensitive to its own business performance, which may also be inconsistent. Currently, the following risks have been identified for the company: Major Risks Share price has been highly volatile over the past 3 months (9.3% average weekly change). Revenue has declined by 98% over the past year. Revenue is less than US$1m (PK₨15m revenue, or US$53k). Market cap is less than US$10m (PK₨1.45b market cap, or US$5.14m).
New Risk • Aug 09New minor risk - Share price stabilityThe company's share price has been volatile over the past 3 months. It is more volatile than 75% of Pakistani stocks, typically moving 8.5% a week. This is considered a minor risk. Share price volatility indicates the stock is highly sensitive to market conditions or economic conditions rather than being sensitive to its own business performance, which may also be inconsistent. It also increases the risk of potential losses in the short term as the stock tends to have larger drops in price more frequently than other stocks. Currently, the following risks have been identified for the company: Major Risks Revenue has declined by 98% over the past year. Revenue is less than US$1m (PK₨15m revenue, or US$53k). Market cap is less than US$10m (PK₨970.9m market cap, or US$3.44m). Minor Risk Share price has been volatile over the past 3 months (8.5% average weekly change).
お知らせ • Aug 01Sitara Peroxide Limited, Annual General Meeting, Aug 22, 2025Sitara Peroxide Limited, Annual General Meeting, Aug 22, 2025.
New Risk • Jul 01New major risk - Financial data availabilityThe company has not reported any financial data. This is considered a major risk. With no or incomplete audited reported financial data, it is virtually impossible to assess the company's investment potential. Currently, the following risks have been identified for the company: Major Risks No financial data reported. Market cap is less than US$10m (PK₨820.4m market cap, or US$2.89m).
New Risk • Mar 30New major risk - Financial data availabilityThe company has not reported any financial data. This is considered a major risk. With no or incomplete audited reported financial data, it is virtually impossible to assess the company's investment potential. Currently, the following risks have been identified for the company: Major Risks No financial data reported. Market cap is less than US$10m (PK₨664.0m market cap, or US$2.37m).
Reported Earnings • Dec 19First quarter 2024 earnings released: PK₨1.43 loss per share (vs PK₨1.98 loss in 1Q 2023)First quarter 2024 results: PK₨1.43 loss per share (improved from PK₨1.98 loss in 1Q 2023). Revenue: PK₨15.9m (down 95% from 1Q 2023). Net loss: PK₨78.8m (loss narrowed 28% from 1Q 2023).
Reported Earnings • Sep 27Full year 2023 earnings released: PK₨14.39 loss per share (vs PK₨6.19 loss in FY 2022)Full year 2023 results: PK₨14.39 loss per share (further deteriorated from PK₨6.19 loss in FY 2022). Revenue: PK₨824.0m (down 53% from FY 2022). Net loss: PK₨792.8m (loss widened 132% from FY 2022).
お知らせ • Sep 27Sitara Peroxide Limited, Annual General Meeting, Oct 10, 2024Sitara Peroxide Limited, Annual General Meeting, Oct 10, 2024.
New Risk • Aug 26New minor risk - Share price stabilityThe company's share price has been volatile over the past 3 months. It is more volatile than 75% of Pakistani stocks, typically moving 7.0% a week. This is considered a minor risk. Share price volatility indicates the stock is highly sensitive to market conditions or economic conditions rather than being sensitive to its own business performance, which may also be inconsistent. It also increases the risk of potential losses in the short term as the stock tends to have larger drops in price more frequently than other stocks. Currently, the following risks have been identified for the company: Major Risks Latest financial reports are more than 1 year old (reported March 2023 fiscal period end). Revenue has declined by 64% over the past year. Market cap is less than US$10m (PK₨783.0m market cap, or US$2.81m). Minor Risks Share price has been volatile over the past 3 months (7.0% average weekly change). Revenue is less than US$5m (PK₨720m revenue, or US$2.6m).
お知らせ • Jul 23Sitara Peroxide Limited, Annual General Meeting, Jul 26, 2024Sitara Peroxide Limited, Annual General Meeting, Jul 26, 2024, at 15:00 Pakistan Standard Time. Agenda: To consider the pending approval of the audited financial statments along with subsequent developments and way-forward; to consider the pending approval of the balancing, modernization and replacement of the company, the financial arrangementas and way-forward; and to consider other matters.
New Risk • May 05New major risk - Financial data availabilityThe company's latest financial reports are more than a year old. Last reported fiscal period ended March 2023. This is considered a major risk. If the company has not reported its earnings on time, it may have been delayed due to audit problems or it may be finding it difficult to reconcile its accounts. In the worst case scenario, it may be facing other major going concern issues jeopardizing its viability as a listed company. Currently, the following risks have been identified for the company: Major Risks Latest financial reports are more than 1 year old (reported March 2023 fiscal period end). Revenue has declined by 64% over the past year. Market cap is less than US$10m (PK₨771.4m market cap, or US$2.77m). Minor Risk Revenue is less than US$5m (PK₨720m revenue, or US$2.6m).
New Risk • Nov 21New minor risk - Financial data availabilityThe company's latest financial reports are more than 6 months old. Last reported fiscal period ended March 2023. This is considered a minor risk. If the company has not reported its earnings on time, it may have been delayed due to audit problems or it may be finding it difficult to reconcile its accounts. Currently, the following risks have been identified for the company: Major Risks Less than 1 year of cash runway based on free cash flow trend (-PK₨139m free cash flow). Share price has been highly volatile over the past 3 months (8.8% average weekly change). Earnings have declined by 56% per year over the past 5 years. Market cap is less than US$10m (PK₨933.9m market cap, or US$3.27m). Minor Risks Latest financial reports are more than 6 months old (reported March 2023 fiscal period end). Revenue is less than US$5m (PK₨720m revenue, or US$2.5m).
New Risk • Oct 18New minor risk - Share price stabilityThe company's share price has been volatile over the past 3 months. It is more volatile than 75% of Pakistani stocks, typically moving 6.2% a week. This is considered a minor risk. Share price volatility indicates the stock is highly sensitive to market conditions or economic conditions rather than being sensitive to its own business performance, which may also be inconsistent. It also increases the risk of potential losses in the short term as the stock tends to have larger drops in price more frequently than other stocks. Currently, the following risks have been identified for the company: Major Risks Less than 1 year of cash runway based on free cash flow trend (-PK₨139m free cash flow). Earnings have declined by 56% per year over the past 5 years. Market cap is less than US$10m (PK₨750.5m market cap, or US$2.71m). Minor Risks Share price has been volatile over the past 3 months (6.2% average weekly change). Revenue is less than US$5m (PK₨720m revenue, or US$2.6m).
Reported Earnings • Apr 08Second quarter 2023 earnings released: PK₨2.01 loss per share (vs PK₨0.13 profit in 2Q 2022)Second quarter 2023 results: PK₨2.01 loss per share (down from PK₨0.13 profit in 2Q 2022). Revenue: PK₨70.6m (down 89% from 2Q 2022). Net loss: PK₨111.0m (down PK₨118.2m from profit in 2Q 2022). Over the last 3 years on average, the company's share price growth rate has exceeded its earnings growth rate by 101 percentage points per year, which is a significant difference in performance.
Board Change • Nov 16Less than half of directors are independentThere is 1 new director who has joined the board in the last 3 years. The new board member was an independent director. The company's board is composed of: 1 new director. 6 experienced directors. No highly experienced directors. 2 independent directors (5 non-independent directors). Independent Director Saim Bin Saeed was the last independent director to join the board, commencing their role in 2022. The following issues are considered to be risks according to the Simply Wall St Risk Model: Minority of independent directors. Insufficient board refreshment.
お知らせ • Nov 12Sitara Peroxide Limited Appoints Yasir Ahmed Awan as ChairmanSitara Peroxide Limited announced that Mr. Yasir Ahmed Awan has been appointed as Chairman of the Board of Directors of the Company and Mr. Imran Ghafoor as Chief Executive Officer for a term of three years.
お知らせ • Aug 19Sitara Peroxide Limited Appoints Saim Bin Saeed as DirectorSitara Peroxide Limited informed Pakistan Stock Exchange that Mr. Saim Bin Saeed has been appointed as Director of the company with effect from August 17, 2022 in place of Mr. Mahmood Ahmad.
お知らせ • Jun 03Sitara Peroxide Limited Announces Resignation of Mahmood Ahmad as DirectorSitara Peroxide Limited informed Pakistan Stock Exchange that Mr. Mahmood Ahmad has resigned from the post of Director of the company with effect from May 30, 2022.
Board Change • Apr 27Less than half of directors are independentNo new directors have joined the board in the last 3 years. The company's board is composed of: No new directors. 7 experienced directors. No highly experienced directors. 2 independent directors (5 non-independent directors). Non-Executive Director Ejaz Hussain was the last director to join the board, commencing their role in 2016. The following issues are considered to be risks according to the Simply Wall St Risk Model: Minority of independent directors. Insufficient board refreshment.
Reported Earnings • Nov 01First quarter 2022 earnings released: PK₨1.80 loss per share (vs PK₨0.92 profit in 1Q 2021)The company reported a poor first quarter result with weaker earnings, revenues and control over costs. First quarter 2022 results: Revenue: PK₨450.5m (down 21% from 1Q 2021). Net loss: PK₨99.0m (down 294% from profit in 1Q 2021). Over the last 3 years on average, earnings per share has fallen by 49% per year but the company’s share price has only fallen by 15% per year, which means it has not declined as severely as earnings.
Price Target Changed • Oct 07Price target decreased to PK₨31.00Down from PK₨36.50, the current price target is provided by 1 analyst. New target price is 43% above last closing price of PK₨21.62. Stock is down 6.3% over the past year.
Reported Earnings • Sep 28Full year 2021 earnings released: EPS PK₨0.63 (vs PK₨1.35 in FY 2020)The company reported a soft full year result with weaker earnings and profit margins, although revenues improved. Full year 2021 results: Revenue: PK₨1.87b (up 6.9% from FY 2020). Net income: PK₨34.7m (down 53% from FY 2020). Profit margin: 1.9% (down from 4.3% in FY 2020). Over the last 3 years on average, earnings per share has fallen by 5% per year but the company’s share price has fallen by 14% per year, which means it is performing significantly worse than earnings.
Valuation Update With 7 Day Price Move • Sep 27Investor sentiment deteriorated over the past weekAfter last week's 16% share price decline to PK₨21.00, the stock trades at a trailing P/E ratio of 5.7x. Average forward P/E is 17x in the Chemicals industry in Pakistan. Total loss to shareholders of 32% over the past three years.
Executive Departure • Jul 13Chief Financial Officer Kamran Zahoor has left the companyDuring their tenure, the company went from making losses to turning a profit. On the 30th of June, Kamran Zahoor left the company after 3.3 in the role. We don't have any record of a personal shareholding under Kamran's name. Kamran is the only executive to leave the company over the last 12 months.
Reported Earnings • May 02Third quarter 2021 earnings released: EPS PK₨0.44 (vs PK₨0.15 in 3Q 2020)The company reported a decent third quarter result with improved earnings and profit margins, although revenues were weaker. Third quarter 2021 results: Revenue: PK₨447.8m (down 3.8% from 3Q 2020). Net income: PK₨24.3m (up 200% from 3Q 2020). Profit margin: 5.4% (up from 1.7% in 3Q 2020). The increase in margin was driven by lower expenses. Over the last 3 years on average, earnings per share has increased by 30% per year but the company’s share price has only increased by 8% per year, which means it is significantly lagging earnings growth.
Reported Earnings • Feb 28Second quarter 2021 earnings released: EPS PK₨0.83 (vs PK₨0.40 loss in 2Q 2020)The company reported a decent second quarter result with improved earnings and profit margins, although revenues were weaker. Second quarter 2021 results: Revenue: PK₨497.2m (down 7.4% from 2Q 2020). Net income: PK₨45.6m (up PK₨67.8m from 2Q 2020). Profit margin: 9.2% (up from net loss in 2Q 2020). The move to profitability was driven by lower expenses. Over the last 3 years on average, earnings per share has increased by 43% per year but the company’s share price has only increased by 19% per year, which means it is significantly lagging earnings growth.
Valuation Update With 7 Day Price Move • Feb 01Investor sentiment improved over the past weekAfter last week's 19% share price gain to PK₨32.76, the stock is trading at a trailing P/E ratio of 15.3x, up from the previous P/E ratio of 12.8x. This compares to an average P/E of 14x in the Chemicals industry in Pakistan. Total returns to shareholders over the past three years are 66%.
Is New 90 Day High Low • Jan 27New 90-day high: PK₨30.16The company is up 36% from its price of PK₨22.13 on 29 October 2020. The Pakistani market is up 10.0% over the last 90 days, indicating the company outperformed over that time. It also outperformed the Chemicals industry, which is up 5.0% over the same period.
Valuation Update With 7 Day Price Move • Jan 06Investor sentiment improved over the past weekAfter last week's 17% share price gain to PK₨26.91, the stock is trading at a trailing P/E ratio of 12.5x, up from the previous P/E ratio of 10.7x. This compares to an average P/E of 13x in the Chemicals industry in Pakistan. Total returns to shareholders over the past three years are 59%.
Is New 90 Day High Low • Jan 05New 90-day high: PK₨25.04The company is up 8.0% from its price of PK₨23.22 on 07 October 2020. The Pakistani market is up 11% over the last 90 days, indicating the company underperformed over that time. However, it outperformed the Chemicals industry, which is up 7.0% over the same period.
Reported Earnings • Oct 23First quarter earnings releasedOver the last 12 months the company has reported total profits of PK₨119.9m, up 67% from the prior year. Total revenue was PK₨1.92b over the last 12 months, up 2.3% from the prior year.
Reported Earnings • Oct 06Full year earnings released - EPS PK₨1.35Over the last 12 months the company has reported total profits of PK₨74.2m, down 64% from the prior year. Total revenue was PK₨1.75b over the last 12 months, down 14% from the prior year. Profit margins were 4.3%, which is lower than the 10% margin from last year. The decrease in margin was driven by lower revenue.
Reported Earnings • Sep 30Full year earnings released - EPS PK₨1.35Over the last 12 months the company has reported total profits of PK₨74.2m, down 64% from the prior year. Total revenue was PK₨1.75b over the last 12 months, down 14% from the prior year. Profit margins were 4.3%, which is lower than the 10% margin from last year. The decrease in margin was driven by lower revenue.